U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Human and Avian Influenza Whole Genome Phage Display Libraries
  1. FDA Technology Transfer Program

Human and Avian Influenza Whole Genome Phage Display Libraries

Human and Avian Influenza Whole Genome Phage Display Libraries

Available for use in developing research reagents, therapeutics or diagnostics are recombinant bacteriophage display libraries for identifying influenza viral gene products in preparation for pandemic threats the cross-reactivity and long-term protection of interpandemic influenza vaccines. Influenza vaccines predominantly include haemagglutinin (HA) and Neuraminidase (NA) antigens that characterize annual circulating influenza types A and type B. Analyses of the immune responses against new candidate vaccines is required in order to identify the best correlate of protection against seasonal human influenza strains and potential pandemic strains.

These "Whole Viral Genome Phage Display Libraries" express complete sets of protein fragments encoded by several Human and Avian Influenza strains including HlN1, H3N2, H5N1 and H7N7 and can be used for in depth analyses of plasma samples from: a) individuals exposed to human influenza; b) individuals exposed to avian influenza; c) individuals vaccinated with traditional influenza vaccines; d) individuals vaccinated with new generation vaccines against human and bird influenza viruses.

Potential Commercial Applications:

  • Serological assays for surveillance of pandemic influenza outbreaks
  • Serological assays for distinguishing between exposure to human and bird influenza strains
  • Serological assays for diagnosing true infections in previously vaccinated individuals
  • Rapid analyses of immune sera from pre-clinical and clinical trials of novel influenza vaccines
  • Mapping of monoclonal and polyclonal antibodies against different influenza gene products
  • Identification of highly conserved "protective" epitopes for inclusion in future broadly-reactive influenza vaccines (against either inter-pandemic or pandemic influenza strains)
  • Studies of viral protein-protein, viral RNA-protein and viral-host protein interactions (viral pathogenesis studies)

Competitive Advantages:



Hana Golding
Surender Khurana

Intellectual Property:
Research Tool -- patent protection is not being pursued for this technology

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-031-2007/0
Updated: August 9, 2015